A brand name and a 200 mg strength do not tell a PCD buyer enough to approve, compare or promote this medicine. By the end, you will know which label details, clinical warnings, quality documents, release-performance records and commercial terms to verify before listing Rozest 200 SR Tablets.
Key takeaways
- Match the strip with approved documents showing aceclofenac 200 mg sustained release.
- Request the supplier’s manufacturing licence, product approval documents, and batch certificate.
- Compare release form, strength, composition, pack, and counselling requirements—not price alone.
- Put territory, expiry returns, complaints, payment, and supply terms in the PCD agreement.
What Rozest 200 SR contains and what the “200 SR” label means
Before treating Rozest 200 SR as an aceclofenac product, match the physical strip with the approved product documents. The composition must identify aceclofenac as the active ingredient, 200 mg per tablet as its strength, and a sustained-release dosage form.
Confirm the manufacturer, manufacturing licence, product permission or marketing authorisation, batch number and expiry date because brand listings can differ between markets.
| Label or record | What you must confirm | Why it matters |
|---|---|---|
| Active ingredient | Aceclofenac | Confirms the medicine is the intended NSAID product |
| Strength | 200 mg aceclofenac per tablet | Establishes what “200” represents; it does not mean 200 tablets or automatically equal two 100 mg tablets |
| Release type | Sustained release, extended release or the approved SR description | Determines how the dose is released and how often it is taken |
| Complete composition | Aceclofenac plus listed excipients and the tablet dosage form | Supports allergy checks, quality review and complaint investigation |
For buyers searching “rozest 200 sr tablets details”, release performance deserves more than an assay result. Request the approved dissolution specification and representative results at the stated test conditions; two tablets can contain 200 mg yet release it at different rates.
Swallow an SR tablet whole unless the approved product information permits splitting. Do not crush or chew it, because that can release the drug too quickly and defeat the intended dosing design.
How the approved label should guide dispensing and patient counselling
Do not promote or supply Rozest 200 SR until its approved product information gives a usable answer for each counselling decision below. A catalogue claim such as “for pain relief” is not a substitute for the named indication, dose, warnings and administration instructions on the approved label.
1. Indication: State the exact approved condition or conditions and the limits of use. Do not extend a label for a named gynaecological indication into unrestricted treatment of every pelvic or menstrual pain complaint.
2. Dose and administration: State the dose, dosing interval, maximum duration and missed-dose instruction. Tell the patient to swallow the sustained-release tablet whole with water; crushing, chewing or splitting can alter drug release unless the approved information expressly permits it.
3. Contraindications: Flag active peptic ulcer or gastrointestinal bleeding, severe renal or hepatic impairment, severe heart failure, NSAID-triggered asthma or hypersensitivity, and pregnancy restrictions, including later pregnancy. Use the exact wording and exceptions in the approved label.
4. Interactions: Identify concurrent NSAIDs or aspirin, anticoagulants, corticosteroids, selective serotonin reuptake inhibitors, diuretics, ACE inhibitors or ARBs, lithium, methotrexate and ciclosporin when the label lists them. The prescriber must assess these before dispensing.
5. Adverse effects: Explain common gastrointestinal effects and urgent signs such as black stools, vomiting blood, breathing difficulty, facial swelling, severe rash, reduced urine or chest symptoms. Record complaints without treating an SR tablet as interchangeable with two immediate-release tablets.
Only the approved label and prescribing information should support promotional claims, substitution advice and patient counselling.
How to compare Rozest 200 SR with other NSAID products
A 200 mg figure does not make two NSAID tablets equivalent. A dependable PCD pharma product comparison checks whether each product contains the same active ingredient, uses the same sustained-release design, supports the same dosing interval, and carries matching approved indications and warnings.
| Variable | What to compare | Why it matters |
|---|---|---|
| Clinical use | Indications, dose interval, treatment duration, and patient restrictions | A cheaper tablet does not remove risks with another systemic NSAID, anticoagulants, antiplatelets, corticosteroids, ACE inhibitors, ARBs, diuretics, lithium, methotrexate, or nephrotoxic medicines. |
| Formulation | Active ingredient, 200 mg strength, SR release type, excipients, and approved substitution instructions | One 200 mg SR tablet is not automatically interchangeable with two 100 mg immediate-release tablets. |
| Release performance | Dissolution specification and representative results at approved test conditions, alongside assay | Two batches can pass assay while releasing drug at materially different rates. |
| Quality evidence | Product specifications, batch certificate of analysis, stability data, manufacturer, and licence details | Catalogue claims or a WhatsApp quotation cannot establish identity, consistency, or remaining shelf life. |
| Commercial terms | Pack size, MRP, batch size, expiry, lead time, minimum order, replacement policy, and territory terms | A low unit price can hide short-dated stock, a large minimum order, or weak replacement protection. |
Ask the supplier for the physical strip and match its ingredient, strength, release wording, manufacturer, and licence details against the dossier. Compare total procurement risk, not just tablet cost; otherwise a product with slower replenishment, poorer documentation, or unsuitable territory terms can become the expensive choice.
Which documents to request from a Rozest supplier in Chandigarh
Approve a rozest tablet supplier in chandigarh only after matching the physical strip with the dossier: active ingredient, 200 mg strength, sustained-release form, manufacturer name, manufacturing licence number, batch number, expiry date and storage conditions. A catalogue entry or WhatsApp quotation is not evidence of permission to sell.
Request these records before listing the product:
- Product permission or marketing authorisation naming the product, strength, dosage form and approved manufacturer.
- Valid manufacturing licence and current product specification, including composition, appearance, assay limits and dissolution limits.
- Executed batch manufacturing or packaging record, or a signed manufacturing summary identifying the batch size and controls.
- Batch certificate of analysis showing assay, content uniformity, dissolution, impurities, microbial results where applicable, batch date and release approval.
- Stability data from long-term and accelerated studies, with storage conditions, test intervals and the proposed shelf life.
- Dissolution method, approved acceptance criteria and representative results from more than one batch; assay alone cannot prove sustained-release performance.
For a rozest 200 sr tablet pcd pharma in chandigarh, separate quality evidence from commercial terms:
| Record | What to verify | Reject or query when |
|---|---|---|
| Regulatory | Permission and licence match the strip | Names or numbers differ |
| Batch | COA matches batch and expiry | Generic or undated COA |
| Stability | Shelf life is supported | No conditions or time points |
| Dissolution | Results meet approved limits | Only assay is supplied |
| Commercial | MOQ, lead time, replacement and territory terms | Remaining shelf life is unclear |
Apply the same test to all pcd pharma products in chandigarh, including any dossier supplied by Macrozz Healthcare.
Related product
 | Rozest-200 SR Tablets by Macrozz Healthcare are a sustained-release formulation designed to provide effective management of hormonal imbalance and gynecological conditions... View product → |
How to protect the PCD arrangement after product approval
Protect the arrangement by treating storage control and territorial rights as written obligations, not informal promises. A PCD appointment does not create regulatory exclusivity; the contract must grant it commercially and state what happens if another distributor is appointed.
Before dispatch and during warehousing, verify:
- The approved label’s temperature, humidity and light-protection instructions.
- Clean, dry storage with recorded temperature and humidity readings.
- Unbroken cartons, seals, strips and outer labels; quarantine damaged or wet stock.
- Expiry at dispatch, batch number and FEFO rotation.
- Long-term or accelerated stability documents supporting the labelled storage conditions under the ICH stability framework.
- Transport records when heat, moisture or prolonged delays could affect pack integrity.
| Contract term | Specify in writing | Dispute prevented |
|---|---|---|
| Territory and duration | Named districts, exclusivity, start date, end date and renewal process | Overlapping appointments |
| Purchase and payment | Minimum order, delivery lead time, credit period and consequences of late payment | Unplanned stock and cash disputes |
| Damaged or short-dated stock | Inspection period, replacement or credit method, freight responsibility and minimum remaining shelf life | Unsaleable inventory |
| Pricing and promotion | Price-revision notice, MRP control, approved artwork, and ownership of promotional materials | Unauthorized claims or margin disputes |
| Compliance and exit | Complaint, recall, adverse-event reporting, records, return, and termination duties | Regulatory gaps after cancellation |
Require written approval for territory changes, substitutions and promotional claims. Keep invoices, batch records, storage logs and delivery acknowledgements together for audit or recall tracing.
Frequently asked questions
What does Rozest 200 SR contain?
The approved composition should identify aceclofenac as the active ingredient, with 200 mg per tablet in a sustained-release dosage form.
How should the approved label guide Rozest 200 SR dispensing?
Use the approved label for the product name, strength, dosage form, storage instructions, warnings, and patient counselling. Do not replace those directions with assumptions based on another NSAID.
What should you compare when evaluating Rozest 200 SR against other NSAIDs?
Compare the active ingredient, strength, sustained-release or immediate-release form, approved indications, warnings, pack details, batch documentation, and supply terms.
Which documents should you request from a Rozest supplier in Chandigarh?
Request a copy of the manufacturer’s drug manufacturing licence, approved product documents or label, current batch certificate of analysis, invoice details, and written arrangements covering supply and complaints.
Keywords
